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Abstract
Background: Metastasis to regional lymph nodes via lymphatic vessels plays a key role in cancer progression. Tumor
lymphangiogenesis is known to promote lymphatic metastasis, and vascular endothelial growth factor C (VEGF-C) is a
critical activator of tumor lymphangiogenesis during the process of metastasis. We previously identified periostin as an
invasion- and angiogenesis-promoting factor in head and neck squamous cell carcinoma (HNSCC). In this study, we
discovered a novel role for periostin in tumor lymphangiogenesis.
Methods and Findings: Periostin overexpression upregulated VEGF-C mRNA expression in HNSCC cells. By using
conditioned media from periostin-overexpressing HNSCC cells, we examined tube formation of lymphatic endothelial cells.
Conditioned media from periostin-overexpressing cells promoted tube formation. To know the correlation between
periostin and VEGF-C, we compared Periostin expression with VEGF-C expression in 54 HNSCC cases by immunohisto-
chemistry. Periostin expression was correlated well with VEGF-C expression in HNSCC cases. Moreover, correlation between
periostin and VEGF-C secretion was observed in serum from HNSCC patients. Interestingly, periostin itself promoted tube
formation of lymphatic endothelial cells independently of VEGF-C. Periostin-promoted lymphangiogenesis was mediated by
Src and Akt activity. Indeed possible correlation between periostin and lymphatic status in periostin-overexpressing
xenograft tumors and HNSCC cases was observed.
Conclusions: Our findings suggest that periostin itself as well as periostin-induced upregulation of VEGF-C may promote
lymphangiogenesis. We suggest that periostin may be a marker for prediction of malignant behaviors in HNSCC and a
potential target for future therapeutic intervention to obstruct tumoral lymphatic invasion and lymphangiogenesis in
HNSCC patients.
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Introduction
Millions of people die each year of metastatic cancer. Metastasis
occurs via the blood or lymphatic vessels or directly into tissues
and body cavities. Although the biochemical mechanisms of
metastasis are poorly understood, the process is thought to be
systematic rather than random [1]. Regional lymph nodes are
frequently the first sites of spread, presumably due to tumor cell
drainage via pre-existing afferent lymphatic vessels and/or newly
formed lymphatic capillaries [2,3]. Head and neck squamous cell
carcinoma (HNSCC) is one of the most common types of human
cancer, with an annual incidence of over 500,000 cases worldwide
[4]. The literature suggests that the most important reason for the
high mortality rate is that the disease is often not diagnosed or
treated until it has reached an advanced stage. Despite aggressive,
multidisciplinary treatment approaches, including preoperative or
postoperative chemotherapy and/or radiotherapy with recon-
structive surgery, 5-year survival of HNSCC has not improved
significantly over the past 20 years [5]. Like most other epithelial
cancers, HNSCC develops in a multistep process through the
accumulation of multiple genetic and epigenetic alterations. The
most important prognostic indicator for HNSCC patients is
metastasis to the cervical lymph nodes or distant organs [6]. We
previously established an HNSCC cell line from a metastatic
lymph node [7] and used an in vitro invasion assay to isolate a
highly invasive clone from this cell line [8]. We then compared the
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transcriptional profiles of parent HNSCC cells and the highly
invasive clone by microarray analysis and identified periostin
(osteoblast-specific factor 2) as the gene most differentially
expressed in the invasive clone [9]. Periostin is a secreted protein
that has been suggested to function as a cell adhesion molecule for
pre-osteoblasts and to participate in osteoblast recruitment,
attachment, and spreading [10,11]. Periostin overexpression
enhanced invasion and anchorage-independent growth in
HNSCC cells [9]. Interestingly, periostin-overexpressing cells
were aggressively invasive and spontaneously metastasized to
cervical lymph nodes and to the lung in an orthotopic mouse
model of HNSCC [9]. Bao et al. also demonstrated that a colon
cancer cell line with low metastatic potential displayed strikingly
accelerated tumor metastatic growth in an animal xenograft model
of metastasis when engineered to overexpress periostin [12]. These
findings indicate that periostin overexpression may be common in
various types of cancer and that periostin may be important for
tumor invasion. Periostin has previously been shown to stimulate
metastatic growth by inducing angiogenesis [12,13] and enhances
VEGF receptor Flk-1/KDR expression in endothelial cells
through an integrin avb3-FAK-mediated signaling pathway [13];
furthermore, recombinant periostin enhances capillary formation
in vitro [14]. Importantly, clinical studies of periostin expression in
human cancers have demonstrated that increased expression of
periostin correlates with the number of tumor blood vessels and
with metastasis [14]. On the other hand, previous immunohisto-
chemical studies showed a possible correlation between periostin
expression and lymph node metastasis in cancer cases [15].
However, there is no study on the role of periostin in tumor
lymphangiogenesis. In the present study, we demonstrate a novel
action of periostin: the direct and indirect promotion of tumor
lymphangiogenesis.
Results
VEGF-C upregulated by periostin overexpression
promotes tube formation of lymphatic endothelial cells
We previously identified periostin as an invasion-promoting
factor by comparing the gene expression profiles of the parent
HNSCC cells (MSCC-1) and a highly invasive clone (MSCC-Inv1)
[9] (Figure 1A). VEGF-C was also upregulated in the highly
invasive clone by microarray analysis (Figure 1A). Increased
VEGF-C expression in MSCC-Inv1 cells relative to parent cells
was observed (Figure 1B). Moreover, in our previous microarray
analysis to compare the gene expression profile between control
and periostin-overexpressing HNSCC cells, VEGF-C was upre-
gulated in periostin-overexpressing cells [9]. Here we confirmed
that ectopic overexpression of periostin upregulated VEGF-C
expression (Figure 1B). Both periostin and VEGF-C were detected
in conditioned media from periostin-overexpressing cells but not
control cells (Figure 1B). VEGF-C is known to be a critical
activator of tumor lymphangiogenesis during the process of
metastasis. Therefore, we examined tube formation of lymphatic
endothelial cell by adding conditioned media from empty vector-
transfected cells or periostin-overexpressing cells to TR-LE cells.
TR-LE cells were previously established as an immortalized rat
lymphatic endothelial cell line [16]. Conditioned media from
periostin-overexpressing cells remarkably promoted tube forma-
tion by TR-LE cells (Figure 1C and 1D).
To demonstrate the effect of the periostin-induced VEGF-C
expression on tube formation, we used the VEGF receptor 3
(VEGFR-3) kinase inhibitor MAZ51, which is reported to block
both VEGF-C- and VEGF-D-induced phosphorylation of
VEGFR-3 in PAE cells [17]. TR-LE cells is known to express
VEGFR-3 [16]. We confirmed that MAZ51 markedly inhibited
VEGF-C-induced tube formation (Figure S2A and S2B). MAZ51
greatly inhibited tube formation induced by conditioned medium
from periostin-overexpressing cells (Figure S2A and S2B). The
inhibition of tube formation by MAZ51 in conditioned medium
from empty vector-transfected cells was also observed. This
inhibition may be accounted for by VEGF-C secretion from
lymphatic endothelial cells themselves. The inhibitory effect of
MAZ51 was low in cells treated with conditioned medium from
empty vector-transfected cells (Figure S2C). These findings
indicate that periostin may promote lymphangiogenesis through
upregulation of VEGF-C.
Correlation of periostin expression with VEGF-C and
lymphatic status in clinical cancer cases
To determine the correlation between periostin and VEGF-C
expression levels in clinical cancer cases, we compared periostin
expression with VEGF-C expression in 54 HNSCC cases by
immunohistochemical analysis. We defined the grading of
periostin and VEGF-C staining as high (over 10% of tumor cells
showing ++ or +++ intensity) or low (no staining or less than 10%
of tumor cells showing + intensity). For the criterium of 10%
positive cells, we considered that HNSCC cases with less than 10%
of tumor cells showing weak/focal immunopositivity was same as
HNSCC case with no positive staining. Figure 2A shows a
representative case of high expression of both periostin and
VEGF-C. Both Periostin and VEGF-C expression were observed
in cytoplasm of HNSCC cells (Figure 2A). Indeed, most cases with
high expression of periostin or VEGF-C showed strong and diffuse
immunopositivity as shown in Figure 2A and most cases with low
expression of periostin or VEGF-C showed no immunopositivity
as shown in Figure S3A. Only a few cases showed the
heterogenous staining (Figure S3B). For the heterogenous staining,
we totally evaluated the number of stained cells and their staining
intensity by checking at least ten fields including superficial, central
and deep invasive areas of the tumor. Of the 54 HNSCC cases,
high expression of periostin was observed in 39 (72.2%) cases and
high expression of VEGF-C in 37 (68.5%) cases (Figure 2B).
Thirty-three of the 39 (84.6%) HNSCC cases with periostin
expression expressed VEGF-C; this correlation was statistically
significant (P,0.001).
As both periostin and VEGF-C are secreted proteins, we
examined the serum levels of periostin and VEGF-C in HNSCC
patients by ELISA. In this study, we used peripheral blood
collected from 81 HNSCC cancer patients. These cases were
different from cases used in immunohistochemical study. Clinical
information including lymph node metastasis, tumor stage and
TNM classification was gathered from surgical records of the
patients (Table S2). In samples from 5 healthy controls, the
periostin serum level was 0 ng/mL and the VEGF-C serum level
less than 11.0 ng/mL (data not shown). Periostin was detected at
11.4 ng/mL in conditioned media from MSCC-Inv1 cells. Based
on these results, a periostin-positive case was defined as having a
serum periostin level .0 ng/mL and a VEGF-C-positive case as
having a serum VEGF-C level $12.0 ng/mL. The percentage of
periostin-positive cases increased with the stage of progression and
with lymph node metastasis (Figure 2C and 2D). The data on
serum levels of periostin and VEGF-C and the relevant clinical
data on the HNSCC patients are listed in Table S2. The
percentage of VEGF-C-positive cases also increased with the stage
of progression and with lymph node metastasis (Figure 2C and
2D). Interestingly, 32.4% of periostin-positive cases but only
18.2% of periostin-negative cases were VEGF-C-positive
(Figure 2E).
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Periostin directly promotes tube formation by lymphatic
endothelial cells
As shown above, we found that periostin expression correlated
well with VEGF-C expression. Periostin has previously been
shown to promote angiogenesis, as demonstrated by several
findings: (i) periostin enhances VEGF receptor Flk-1/KDR
expression in endothelial cells through an integrin avb3-FAK-
mediated signaling pathway [13], (ii) recombinant periostin
enhances capillary formation [12], and (iii) increased expression
of periostin is correlated with the number of blood vessels and with
metastasis in HNSCC [14]. On the other hand, clinico-patholog-
ical studies showed that periostin was well correlated with lymph
node metastasis in various cancers [15]. These findings made us
hypothesize that periostin might directly affect to lymphatic
endothelial cells in similar to vascular endothelial cells. Therefore,
we investigated whether periostin might directly promote
lymphangiogenesis. We examined the effect of periostin on tube
formation by TR-LE cells. In previous reports, 100 ng/mL of
recombinant periostin protein was used for in vitro experiments
[12,13]. Shao et al. examined Flk1 expression after treatment with
recombinant periostin (0, 50, 100 and 250 ng/mL). As 100 ng/
mL of periostin remarkably upregulated Flk1 expression, they used
100 ng/mL of periostin in their studies. In our ELISA analysis, we
detected 11.4 ng/mL of periostin in conditioned media from
MSCC-Inv1 cells. In addition, we detected from 0 to 15.1 ng/mL
Figure 1. Involvement of VEGF-C promoted by Periostin overexpression on the tube formation of TR-LE cells. (A) Schema shows the
strategy to identify Periostin and VEGF-C by comparing the gene expression profile between the parent (MSCC-1 cells) and a highly invasive clone
(MSCC-Inv1 cells). (B) Higher expression of VEGF-C mRNA in cells of the highly invasive clone MSCC-Inv1 and VEGF-C expression in periostin-
overexpressing cells. HSC4 cells without periostin expression were transduced using a retroviral plasmid encoding hexa-histidine-tagged periostin.
Periostin and VEGF-C mRNA expression levels in MSCC-1 cells, MSCC-Inv1 cells, empty vector-transfected HSC4 cells (empty), and periostin-
overexpressing HSC4 cells (His-periostin) were examined by RT-PCR. GAPDH expression was used as a loading control. Conditioned media were
collected from empty vector-transfected HSC4 cells (empty) and periostin-overexpressing HSC4 cells (His-periostin) after incubation for 4 days.
Conditioned media were concentrated and analysed by western blotting for expression of His-periostin and VEGF-C in conditioned media. (C)
Conditioned media from periostin-overexpressing cells promotes tube formation of lymphatic endothelial cells. Tube formation of TR-LE cells by
adding conditioned media from periostin-overexpressing cells. TR-LE cells were seeded onto matrigel-coated wells in the presence of conditioned
media from empty vector-transfected (control CM) or periostin-overexpressing (periostin CM) HSC4 cells. After incubation for 0–9 h, the lengths of
the tube-like structures formed were evaluated. The figure shows the cells after incubation for 9 h. (D) The graph shows the tube scores after 0–9 h
incubation of control CM or periostin CM. The bars show the average values and SDs from 3 independent experiments.
doi:10.1371/journal.pone.0044488.g001
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Figure 2. Correlation between periostin and VEGF-C in HNSCC. (A) Immunohistochemical staining for periostin and VEGF-C in HNSCC cases.
Representative HNSCC cases (high and low magnification) with periostin and VEGF-C expression are shown. Scale bar is shown in each picture. (B)
Graph shows the VEGF-C expression status in HNSCC cases with high or low expression of periostin. (C) Serum level of periostin and VEGF-C in 81
HNSCC patients was examined by ELISA. Serum level of periostin and VEGF-C was compared with tumor stage. Graph shows percentage of periostin
or VEGF-C positive cases in different tumor stage (from stage 1 to 4). (D) Serum level of periostin and VEGF-C was compared with lymph node
metastasis. Graph shows percentage of periostin or VEGF-C positive cases in cases with or without lymph node metastasis (E) Serum level of periostin
was compared with serum level of VEGF-C. Graph shows percentage of VEGF-C positive cases in cases with periostin positive or negative.
doi:10.1371/journal.pone.0044488.g002
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of periostin in serum from HNSCC patient (Table S2). Although
100 ng/mL of periostin seems to be high concentration, we
thought that concentration of periostin may be higher in local
tumor area than in serum. In addition, we found that periostin
promoted tube formation in a concentration dependent manner
(0, 50, 100 and 200 ng/mL) (Figure S4), and the effect of 100 ng/
ml of periostin on tube formation is remarkable (Figure 3A-C and
Figure S4). Although 100 ng/ml of periostin seems to be higher
level in comparison with physiological level, we used 100 ng/ml of
periostin in the following studies. 100 ng/mL of VEGF-C was
used as a positive control for lymphangiogenesis. In various
studies, 100 ng/mL of VEGF-C was used for in vitro experiments
[18–20]. Interestingly, treatment with recombinant periostin
promoted tube formation relative to no treatment (Figure 3A
and 3B). Surprisingly, the effect of periostin on tube formation was
similar to that of VEGF-C (Figure 3C). Moreover, co-treatment
with periostin and VEGF-C markedly promoted tube formation
(Figure 3D and 3E).
We investigated how periostin promotes lymphangiogenesis by
using western blotting with phosphorylation-specific antibodies to
determine the activity levels of cell signaling molecules, such as
Src, Akt, ERK and FAK, in periostin-treated TR-LE cells. Src and
Akt but not ERK and FAK were activated by recombinant
periostin treatment (Figure 3F). To confirm the role of Src and Akt
in periostin promoted lymphangiogenesis, we used SU6656 to
inhibit Src activity and LY294002 to inhibit Akt activity. These
kinase inhibitors inhibited periostin-induced tube formation by
TR-LE cells (Figure 3G and 3H), suggesting that periostin-induced
lymphangiogenesis may be mediated by Src and Akt activity.
Next, we examined the effect of periostin on proliferation and
migration of TR-LE cells. Recombinant periostin only slightly
promoted cell growth (Figure 4A) but greatly promoted migration
(Figure 4B). Focal adherens, which are clusters of integrins with
accumulation of multiple cytoskeletal and signaling proteins
around the integrin cytoplasmic domains, have significant effects
on cell migration and signaling. Therefore, we examined the effect
of periostin on the formation of focal adhesions. We seeded
trypsinized TR-LE cells on cover slips coated with PBS or
recombinant periostin and stained for focal adhesions with anti-
vinculin antibody and for F-actin with phalloidin. TR-LE cells
efficiently attached and rapidly recovered their morphology on
periostin-coated cover slips compared with PBS-coated cover slips
(Figure 4C). Notably, TR-LE cells formed numerous vinculin-
containing focal adhesions on the periostin-coated but not the
PBS-coated cover slips (Figure 4C). Enhancement of tube
formation by periostin may be affected by promotion of migration
and increased focal adhesions.
Periostin expression correlates well with the number of
lymphatic endothelial cells in clinical cancer specimens
To know the role of periostin in tumor lymphangiogenesis in
vivo, we confirmed the correlation between periostin expression
and the number of lymphatic vessels in a tumor xenograft model
in nude mice. We previously injected control or periostin-
overexpressing HNSCC cells subcutaneously into nude mice and
found that transplanted periostin-overexpressing cells produced
comparatively larger tumor volume after 28 days than did empty
vector-transfected cells [9] (Figure S5). We used these tumor
tissues (10 control and 10 periostin-overexpressing tumors) to
count the numbers of lymphatic vessels expressing LYVE-1, which
was specifically observed in lymph vessels in both control and
periostin-overexpressing tumors (Figure 5A and Figure S4).
Interestingly, the number of lymph vessels was significantly higher
in periostin-overexpressing tumors (36.3611.1) than in control
tumors (14.9562.0) (Figure 5B).
Finally, we examined the correlation between periostin expres-
sion and lymphatic status in HNSCC cases by immunohistochem-
istry using the D2-40 antibody. The D2-40 antibody specifically
recognized lymphatic endothelial cells but not blood vessels (data
not shown). Lymphatic vessels were unevenly distributed through-
out the tumors. We counted the number of lymphatic vessels in the
intratumoral (within the tumor) and peritumoral (within 1 mm of
the invasive front) areas. HNSCC cases with periostin expression
tended to have higher numbers of lymphatic vessels in both the
intratumoral and peritumoral areas (Figure 6A and 6B), but this
correlation was not statistically significant. As expected, D2-40
immunostaining highlighted the presence of lymphatic invasion.
Of 54 HNSCC cases, 27 (50%) exhibited lymphatic vessel invasion
by tumor cells. Strikingly, periostin expression was observed in 25
of 27 HNSCC cases with lymphatic invasion (Figure 6C). Periostin
expression was significantly correlated with lymphatic invasion
(P,0.001).
Discussion
The overall 5-year survival rate for HNSCC, one of the most
common cancers, is low, largely due to the propensity of some
tumors to disseminate via the lymphatics. Indeed, lymph node
involvement is one of the strongest poor prognostic indicators.
Recent studies using animal models suggest that solid tumors can
induce lymphangiogenesis that may in turn promote tumor spread
[21]. Moreover, lymphangiogenesis can occur adjacent to or
within cancers and correlates with lymph node metastasis [22,23].
We have previously shown that the number of lymph vessels in
both intratumoral and peritumoral areas was well associated with
an increased tendency for nodal metastasis in HNSCC [24]. While
lymphangiogenesis in primary tumors is known to predict nodal
metastasis, its mechanism remains unclear.
We previously identified periostin as an invasion-promoting
factor by comparing the gene expression profiles of parent and
highly invasive clone HNSCC cells [9]. Periostin, originally called
osteoblast-specific factor-2 (Osf2), was first identified in bone,
where it was implicated in regulating osteoblast adhesion and
differentiation [10,25]. Cumulative evidence shows that high
expression of periostin is frequently observed in various cancers
and correlates well with malignant behavior [15]. Recently,
periostin has been revealed to stimulate metastatic growth by
inducing angiogenesis [13,14]. Periostin secreted by tumor cells
acts in a paracrine manner to augment the survival of endothelial
cells and induces neovascularization, consistent with the notion
that enhanced survival of intratumoral endothelial cells is critical
for successful tumor angiogenesis [26–28]. Our previous micro-
array analysis of parent and highly invasive clone HNSCC cells
found that VEGF-C was upregulated in the highly invasive cells
[9] (Figure 1A and 1B). Indeed, periostin overexpression induced
the upregulation of VEGF-C expression in HNSCC cells, and
VEGF-C protein was secreted from periostin-overexpressing
HNSCC cells (Figure 1B). VEGF-C, the original Flt-4/VEGFR-
3 ligand [29,30], is a member of the VEGF family of polypeptide
growth factors, which comprises VEGF-A, -B, -C, -D and the
parapoxvirus Orf virus VEGFs [31,32]. Based on its expression
profile and its binding to Flt-4, VEGF-C has been implicated in
the development of the lymphatic system [33,34]. Moreover,
transgenic overexpression of VEGF-C under the keratin 14
promoter induces lymphatic vessel enlargement in the skin [35],
and recombinant VEGF-C induces lymphangiogenesis in the
chick chorioallantoic membrane [36]. Activation of the VEGF-C/
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PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e44488
Figure 3. Direct involvement of periostin in tube formation of lymphatic endothelial cells. (A) TR-LE cells were seeded onto matrigel-
coated wells in the presence of periostin (100 or 200 ng/mL) or VEGF-C (100 ng/mL). After incubation for 1–9 h, the lengths of the tube-like
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Flt-4 axis in lymphatic endothelial cells can facilitate metastasis by
increasing the formation of lymphatic vessels within and around
tumors [37]. The VEGF-C/Flt-4 axis is therefore expressed not
only by lymphatic endothelial cells but also by a variety of human
tumor cells. As we expected, conditioned media from periostin-
overexpressing HNSCC cells promoted tube formation of
lymphatic endothelial cells. Moreover, the VEGFR-3 kinase
inhibitor inhibited the tube formation induced by conditioned
medium from periostin-overexpressing cells, suggesting that
periostin-promoted lymphangiogenesis may be caused in part by
increased secretion of VEGF-C from cancer cells (Figure S2B). By
using clinical samples, we demonstrated that periostin expression
correlated well with VEGF-C expression in HNSCC cases by
immunohistochemistry and that serum periostin level correlated
well with that of VEGF-C in HNSCC patients (Figure 2E). In this
study, we could not detect periostin in serum from 5 normal
healthy volunteers. Previous reports showed that wild range of
serum periostin (0.2–194 ng/mL) was detected in normal healthy
volunteers [35–38]. Thus, serum level of periostin in normal
healthy volunteers seems to be controversial, and it is still unclear
whether periostin is produced by normal cells or not. In the future,
we will examine the serum level of periostin in the large number of
normal healthy volunteers. However, all reports including the
present study showed that increased level of periostin was observed
in cancer patients [38–41]. Importantly, serum level of periostin
and VEGF-C was well correlated with tumor progression
including lymph node metastasis. Although we have to examine
the relationship between protein-expression level of primary tumor
and serum level in a large number of HNSCC cases, detection of
serum level of periostin and VEGF-C may be a useful for
prediction of malignant behaviors of HNSCC patients.
Surprisingly, recombinant periostin directly promoted tube
formation by lymphatic endothelial cells. Moreover, periostin
activated Src and Akt in TR-LE cells (Figure 3F) and inhibition of
Src or Akt inhibitor suppressed tube formation driven by periostin
(Figure 3G and 3H). Previous studies show that c-Src regulates the
formation of the complex between VEGFR-2 and integrin avb3
by phosphorylating the cytoplasmic tyrosine residues of integrin b3
inducing structural changes on the complex that promote capillary
formation and chemotaxis [42,43], and that c-Src phosphorylates
the C-terminal domain of VEGFR-3 at several residues including
those critical for the activation of downstream signaling [44]. We
previously found that interference with the function of integrins by
specific anti-avb3 and anti-avb5 integrin antibodies had an effect
on the ability of periostin to mediate cell adhesion in HNSCC cells
[9]. Moreover, previous report that periostin activated the Akt/
PKB pathway via the avb3 integrin to promote cellular survival in
colon cancer [12]. Therefore, these finding suggest that periostin-
integrin interaction may trigger the intracellular signaling and
activation of certain genes that are involved in tube formation and
migration of lymphatic endothelial cells through Src and Akt
activation. Indeed, several recent reports show that Src and Akt
are involved in lymphangiogenesis: (i) loss of Akt1 reduces
lymphatic capillary size and causes defects in the maturation of
collecting lymphatic vessels and in valve development [45], (ii)
VEGFR-3 mediates activation of Akt as well as the Erk1/2
pathways in primary lymphatic endothelial cells [46] and (iii)
inhibition of Src kinase is strongly anti-lymphangiogenic in vitro
and in vivo [47]. In addition to promoting tube formation, periostin
promoted migration and formation of focal adherens (Figure 4B
and 4C). These phenotypes may play an important role in
periostin-mediated lymphangiogenesis. To our knowledge, this is
the first report containing in vitro data on the roles of periostin in
tumor lymphangiogenesis. However, detailed molecular mecha-
nism of periostin-driven lmphangiogenesis is still unclear. In
endothelial cells, periostin promotes angiogenesis via the upregu-
lation of Flk-1/KDR expression through the integrin avb3-FAK-
mediated signaling pathway [13]. Therefore, we hypothesized that
periostin might upregulate expression of the VEGF-C receptor Flt-
4 in lymphatic endothelial cells; however, this was not the case
(Figure S2A and S2B). Although ectopic overexpression of
periostin induced upregulation of VEGF-C in HNSCC cells,
treatment with recombinant periostin did not induce upregulation
of VEGF-C in lymphatic endothelial cells (Figure S6A and S6B).
This discrepancy may be accounted by the cell type. A previous
report shows that proinflammatory cytokines such as IL-1a, IL-1b,
and TNF-a upregulate VEGF-C mRNA expression [48]. How-
ever, the detailed mechanism of VEGF-C induction remains
unclear, making it interesting to elucidate the mechanism by
which periostin upregulates VEGF-C.
Increased number of lymph vessels was observed in xenograft
tumors of periostin-overexpressing HNSCC cells (Figure 5A and
5B), and periostin expression positively correlated with the number
of lymph vessels and with lymphatic invasion in HNSCC cases
(Figure 6A–C). In non-small-cell lung cancer, periostin expression
also correlates well with lymphatic microvessel density [49].
Moreover, several immunohistochemical studies have found
possible correlations between periostin expression and lymph
node metastasis in cancer cases including HNSCC, gastric cancer
cholangiocarcinoma, thyroid cancer, pancreatic cancer and
melanoma [9,14,50–54]. It is interesting to examine the correla-
tion between periostin and lymhangiogenesis in these types of
cancer.
In conclusion, we have demonstrated that periostin has a novel
function as a direct and/or indirect promoter of tumor
lymphangiogenesis. Periostin-promoted lymphangiogenesis was
mediated by increased secretion of VEGF-C from cancer cells
and by migration and tube formation via activation of Src and Akt
in lymphatic endothelial cells (Figure 7). Importantly, the serum
periostin level in HNSCC patients correlated well with that of
structures formed were evaluated. The figure shows cells after incubation for 9 h. (B) The graph shows the tube scores after incubation for 1–9 h. The
bars show the average values and SDs from 3 independent experiments. (C) The graph shows the tube score ratios after treatment with VEGF-C or
periostin for 9 h. The tube score of control was defined as 1.0. (D) TR-LE cells were seeded onto matrigel-coated wells in the presence of periostin
(100 ng/mL) and VEGF-C (100 ng/mL). After incubation for 1–9 h, the lengths of the tube-like structures formed were evaluated. The graph shows the
tube score after incubation for 1–9 h. The bars show the average values and SDs from 3 independent experiments. (E) The graph shows the tube
score ratios after treatment with VEGF-C and periostin for 9 h. The tube score of control was defined as 1.0. (F) Periostin promotes Src and Akt
phosphorylation. Levels of total and phosphorylated forms of Src, Akt, ERK, and FAK after treatment of TR-LE cells with periostin (100 ng/mL) shown
by western blotting. b-actin expression was used as a loading control. (G) The lengths of the tube-like structures formed by TR-LE cells incubated for
1–9 h with recombinant periostin (100 ng/mL) with or without SU6656 (400 nM) were evaluated. The upper graph shows the tube scores after
incubation for 1–9 h. The bars show the average values and SDs from 3 independent experiments. The lower graph shows the tube score ratio. The
tube score of control was defined as 1.0. (H) The lengths of the tube-like structures formed by TR-LE cells incubated for 1–9 h with recombinant
periostin (100 ng/mL) with or without LY294002 (10 mM) were evaluated. The upper graph shows the tube scores after incubation for 1–9 h. The bars
show the average values and SDs from 3 independent experiments. The lower graph shows the tube score ratio. The tube score of control was
defined as 1.0.
doi:10.1371/journal.pone.0044488.g003
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VEGF-C and with malignant behaviors including increased tumor
stage and lymph node metastasis. Therefore, periostin could be a
marker for prediction of malignant behaviors in HNSCC. Our
present and previous findings reveal that periostin may play
important roles in metastasis through promotion of invasion,
angiogenesis, and lymphangiogenesis. We conclude that periostin
may be a potential target for future therapeutic intervention to
obstruct tumoral lymphatic invasion, angiogenesis, and lymphan-
giogenesis in HNSCC patients.
Materials and Methods
Reagents
Human recombinant VEGF-C protein was obtained from R&D
Systems (Minneapolis, MN). Human recombinant periostin
protein was obtained from PROSPEC (East Brunswick, NJ).
The inhibitors of VEGF receptor 3 kinase (MAZ51), Src
(SU6656), and PI3 Kinase (LY294002) were obtained from
Calbiochem (San Diego, CA).
Figure 4. Periostin promotes proliferation and migration of lymphatic endothelial cells. (A) Proliferation of TR-LE cells after recombinant
periostin treatment. Cells were seeded onto fibronectin-coated 24-well plates at 1.56104/well. After pre-incubation at 33uC for 24 h, the temperature
was changed and recombinant periostin (100 ng/mL) was added to the medium. The cells were trypsinized and counted 0, 2, 4, or 6 days after the
addition of recombinant periostin. The bars show the average values and SDs from 3 independent experiments. (B) The effect of periostin on cell
migration of TR-LE cells. Cells were seeded onto filters pre-coated with 10 mg of fibronectin. The lower compartment contained 0.5 mL of serum-free
medium with or without 100 ng/mL recombinant periostin. After incubation for 4 h, cells that had migrated to the lower surfaces of the filters were
visualized by hematoxylin staining and counted. The assay was repeated 3 times. The figure shows cells that had migrated to the lower surface of the
filter (upper panel). The graph shows the number of cells on the lower surfaces of the filters with or without periostin (100 ng/mL) (lower panel). (C)
TR-LE cells were seeded on cover slips coated with PBS or recombinant periostin (200 ng/mL) and allowed to attach for 60, 120, 180, or 240 min. The
cells were stained with Alexa Fluor 488-phalloidin antibody and anti-vinculin-FITC antibody. DNA was visualized by 49,6-diamidino-2-phenylindole
(DAPI) staining.
doi:10.1371/journal.pone.0044488.g004
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Cell culture
MSCC-1 and MSCC-Inv1 cells were previously established in
our laboratory [7,8] and were maintained in Keratinocyte-SFM
(Invitrogen, San Diego, CA) under 5% CO2 in room air at 37uC.
MSCC-1 cells were established from lymph node metastatic tumor
tissue of a patient with gingival squamous cell carcinoma [7].
MSCC-Inv1 cells were isolated from MSCC-1 cells by using an in
vitro invasion assay device [8]. HNSCC cell lines HSC4 and Ca9-
22 were provided by the Japanese Collection of Research
Bioresources Cell Bank and maintained in RPMI-1640 (Nissui
Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-
inactivated foetal bovine serum (FBS) (Invitrogen) and 100 U/mL
penicillin-streptomycin (Invitrogen) under 5% CO2 in room air at
37uC. On receiving the cell lines, they were immediately cultured
and expanded to prepare frozen ampule stocks. Cells were
passaged for no more than 2 to 3 months before establishing new
culture from early-passage frozen ampules. Periostin-overexpress-
ing HSC4 and Ca9-22 cells were previously obtained by
transfection with a retroviral plasmid encoding hexa-histidine-
tagged periostin [14]. Immortalized rat lymphatic endothelial cell
line, TR-LE cell was established from thoracic duct of tsA58
transgenic rats [16]. They were maintained on culture dishes pre-
coated with 10 mg/mL fibronectin (Iwaki Glass, Tokyo, Japan) in
HuMedia-EG2 (Kurabo, Osaka, Japan) supplemented with 10%
FBS at a permissive temperature (33uC). For the growth assay, the
cells were plated onto 24-well plates (Falcon Becton Dickinson,
Franklin Lakes, NJ), trypsinized, and counted using a Cell Counter
(Coulter Z1, Coulter Co., Hialcah, FL). All of the cell lines used
the course of these studies were maintained in continuous culture
for 3 months or less.
Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from tumor tissues and cell lines using
the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA concen-
tration was quantified and its purity determined by standard
spectrophotometric methods. cDNA was synthesized from 1 mg
total RNA using ReverTra Dash (Toyobo Biochemicals, Tokyo,
Japan) according to the manufacturer’s instructions. The primer
pair sequences used were: human periostin, 59-gatggagtgcctgtg-
gaaat-39 (forward) and 59-aacttcctcacgggtgtgtc-39 (reverse) (prod-
uct size: 239 bp); human VEGF-C, 59-ggaaagaagttccaccacca-39
(forward) and 59-tttgttagcatggacccaca-39 (reverse) (product size:
249 bp); human GAPDH, 59-accacagtccatgccatcac-39 (forward)
and 59-tccaccaccctgttgctgta-39 (reverse) (product size: 452 bp).
Total cDNA was amplified using Go TaqH Green Master Mix
(Promega, Madison, WI) in a PC701 thermal cycler (Astec,
Fukuoka, Japan) for 25–30 cycles of denaturation at 94uC for 20 s,
annealing at 60uC for 30 s, and extension at 72uC for 1 min (for all
primers). The amplicons were resolved on 1.5% agarose/TAE gels
(Nacalai tesque, Inc., Kyoto, Japan) at 100 mV and visualized by
ethidium bromide staining.
Figure 5. Periostin promotes lymphangiogenesis in vivo. (A) Periostin-overexpressing (periostin) and empty vector-transfected (control) HSC2
cells (16107 cells) were individually injected subcutaneously at 2 sites in each of 5 nude mice. After 1 month, the tumors were resected and stained
with an anti-mouse LYVE-1 antibody recognising lymphatic vessels. Representative cases of immunohistochemical staining for LYVE-1 in control and
periostin-overexpressing tumors are shown. Arrow shows LYVE-1 positive lymphatic vessels. (B) The LYVE-1 positive lymphatic vessels in control and
periostin-overexpressing tumors were counted. The graph shows the average numbers of lymphatic vessels in control and periostin-overexpressing
tumors. The bars show the average values and SDs.
doi:10.1371/journal.pone.0044488.g005
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Western blot analysis
Western blotting was performed as previously described [9].
Sample protein concentrations were measured by Bradford
protein assay (Bio-Rad, Richmond, CA), and 20 mg total
protein/lane subjected to electrophoresis on 10% polyacrylamide
gels followed by electroblotting onto nitrocellulose filters. The
membranes were blocked with 3% milk in TBS-T and incubated
overnight at 4uC with the following antibodies: anti-b-actin
monoclonal antibody (Sigma, St. Louis, MO), anti-His-tag
polyclonal antibody (Cell Signaling Technology, Beverly, MA),
anti-phospho-FAK (Tyr576/Tyr577) monoclonal antibody (Cell
Signaling Technology), anti-phospho-Akt (Ser473) monoclonal
antibody (Cell Signaling Technology), anti-phospho-Src (Tyr416)
polyclonal antibody (Cell Signaling Technology), anti-phospho-
ERK monoclonal antibody (Santa Cruz Biotechnology, Inc.), anti-
FAK polyclonal antibody (Cell Signaling Technology), anti-Akt
polyclonal antibody (Cell Signaling Technology), anti-Src poly-
clonal antibody (Cell Signaling Technology), and anti-ERK
monoclonal antibody (Cell Signaling Technology). The mem-
branes were then washed with TBS-T and incubated with specific
secondary antibodies and the proteins visualized using the ECL
western blotting detection system (Amersham, Piscataway, NJ).
Patient samples
Archived paraffin-embedded tissue specimens from 54 previ-
ously untreated HNSCC patients were obtained from the
Department of Oral Pathology, Faculty of Dental Sciences,
University of Peradeniya, Sri Lanka after approval by the Ethical
Committees of all involved institutions. Clinical information
including age, sex, location and lymphatic invasion was gathered
from surgical records of the patients (Table S1). All received
surgery as their first-line treatment, with some receiving postop-
erative radiotherapy.
Peripheral blood was collected from 81 current HNSCC cancer
patients. Forty-four samples were obtained from the Department
of Oral and Maxillofacial Sciences, Gifu University Graduate
School of Medicine and 37 from Cancer Hospital in Ho Chi Minh
(Vietnam) after approval by the Ethical Committees of the
respective institutions. Blood samples were centrifuged and plasma
separated and frozen in aliquots at -80uC for later analysis.
Clinical information including lymph node metastasis, tumor stage
and TNM classification was gathered from surgical records of the
patients (Table S2).
Immunohistochemical staining
The tumor tissues were fixed in 10% formalin, embedded in
paraffin, and cut into 4-mm-thick sections. The sections were
stained with hematoxylin and eosin (H&E) for histological
examination. Immunohistochemical detection of periostin,
VEGF-C and D2-40 in HNSCC cases was performed on
4.5 mm sections mounted on silicon-coated glass slides, using the
EnVision system (DAKO, Glostrup, Denmark). A polyclonal anti-
Periostin antibody was generated by immunizing the rabbits with
specific peptides (EGEPEFRLIKEGETC) for periostin and
purified through an affinity column. We previously confirmed
Figure 6. Correlation between periostin expression and lymphatic status in clinical HNSCC cases. (A) Periostin and D2-40 expression
levels were examined by immunohistochemical staining of HNSCC case specimens. A representative case of periostin and D2-40 expression in HNSCC
is shown. Arrow shows D2-40 positive lymphatic vessels. (B) The graph shows the comparison between the average numbers of lymph vessels in
intratumoral, peritumoral, and total areas in HNSCC cases with high or low expression of periostin. (C) The graph shows the status of lymphatic
invasion in HNSCC cases with high or low expression of periostin.
doi:10.1371/journal.pone.0044488.g006
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the specificity of this antibody by recognizing a recombinant
Periostin protein, ectopic overexpressing His-tagged periostin in
lysates and secreted Periostin protein in a conditioned media from
periostin-overexpressing cells [15]. Anti-D2-40 monoclonal anti-
body (Signet, Dedham, MA; dilution 1:40) and anti-VEGF-C
polyclonal antibody (C-20, Santa Cruz Biotechnology, Santa
Cruz, CA; dilution 1:25) were also used. The specific secondary
antibody was then added and visualized with diaminobenzidine
(DAB). For the evaluation of staining intensity, we graded +
(weak/focal immunopositivity), ++ (strong/focal immunopositivity
and weak/diffuse immunopositivity) and +++ (strong/diffuse
immunopositivity). Then, the expression of periostin and VEGF-
C was graded as high (over 10% of tumor cells showing ++ or +++
intensity) or low (no staining or less than 10% of tumor cells
showing + intensity).In HNSCC cases with the heterogenous
staining, we observed at least ten fields including superficial,
central and deep invasive areas of the tumor. Then we totally
evaluated the number of stained cells and their staining intensity as
described above. For periostin expression, as periodontal ligament
expresses periostin [10], we used a specimen of gingival cancer
cases with periodontal tissue as an internal positive control (Figure
S1A). When the slides were visualized with DAB staining, we used
this specimen as a positive control for assessment of intensity of
staining. Negative controls were processed as above except for the
primary antibody was used. In addition, as several slides of
HNSCC cases include the normal oral mucosa, we used the
staining of normal epithelial cells as a negative control of periostin
(Figure S1B). For VEGF-C expression, specificity of antibody was
checked by staining without primary antibody. Moreover, we
confirmed the positivity by using this antibody in VEGF-C positive
HNSCC cell line by immunohistochemistry (data not shown). One
specimen of HNSCC case with VEGF-C positive staining was
used for assessment of intensity of staining. As several slides of
HNSCC cases include the normal oral mucosa, we used the
staining of normal epithelial cells as a negative control of
VEGF-C.
Evaluation of intratumoral and peritumoral
lymphangiogenesis
We used one section (4.5 mm) of each tumor. After staining with
D2-40, We counted the number of lymphatic vessels in 6 high-
power fields (6100) with the highest lymphatic vascular density
(hot spots); within the tumor and within an area 1 mm from the
tumor border (along the invasive front) in each tumor section.
Each selected field was micro-photographed and the positively
Figure 7. A model of periostin-promoted lymphangiogenesis. Periostin expression is upregulated in cancer cells. Periostin in turn upregulates
VEGF-C expression in cancer cells. Periostin secreted from the cancer cells promotes migration and tube formation of lymphatic endothelial cells
through the activation of Src and Akt. Src may activate VEGFR-2 and VEGFR-3 [36–38]. Moreover, Secreted VEGF-C from cancer cells also promotes
migration and tube formation of lymphatic endothelial cells. Thus, in addition to activation of VEGF-C signaling pathway, periostin-integrin
interaction may trigger the intracellular signaling and activation of certain genes that are involved in tube formation and migration of lymphatic
endothelial cells through Src and Akt activation.
doi:10.1371/journal.pone.0044488.g007
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stained lymph vessels traced using Adobe Photoshop software.
Total vessel counts averaged over the 6 high-power fields (6100)
were obtained from each tumor. For evaluating the invasion of
tumor cells into lymphatic vessels, the whole tumor area was
scanned.
ELISA
Periostin levels were determined using sandwich enzyme-linked
immunosorbent assay (ELISA) kits provided by Immuno-Biolog-
ical Laboratories Co., Ltd. (Gunma, Japan). The VEGF-C levels
were determined using commercially available sandwich ELISA
kits (human VEGF-C ELISA kit; Immuno-Biological Laboratories
Co., Ltd.). Briefly, serum samples were incubated in a micro-well
plate pre-coated with rabbit anti-human periostin IgG or rabbit
anti-human VEGF-C IgG. Any target protein present in the
samples thus bound to the wells, and the excess was removed by
extensive washing. The amount of periostin or VEGF-C was
measured using a peroxidase-conjugated secondary antibody
detected by the addition of tetramethylbenzidine (TMB). The
reactions were stopped with an acid solution and the optical
density at 450 nm read in a micro-titer plate spectrophotometer.
The serum target protein concentrations were determined from
corresponding standard curves run separately for each plate.
Tube formation assay
Sub-confluent TR-LE cells were harvested with trypsin-EDTA,
centrifuged at 1200 rpm for 5 min, suspended (66104) in
HuMedia-EG2 (Kurabo) without growth factors or FBS, and
seeded in a 24-well plate pre-coated with 200 mL of 10 mg/mL
matrigel (Falcon Becton Dickinson). After incubation at 37uC for
1–9 h, the cells were photographed with an epifluorescence Zeiss
Axioplan 2 (Zeiss Inc., Thorwood, NY) microscope attached to a
CCD camera. The lengths of the tube-like structures formed were
measured by Chalkley Counting modified. Briefly, the four most
vascular areas (hot spots) with the highest number of microvessel
profiles were chosen subjectively from each well. A 25-point
Chalkley eyepiece graticule was applied to each hot-spot area and
oriented to permit the maximum number of points to hit on, or
within the areas. The Chalkley count is the number of grid points
that hit microvessels. The Chalkley count for an individual well
was taken as the mean value of the four graticule counts. All
Chalkley counts were performed by one observer and used the
microscope with the lowest maginification.
Migration assay
Cell migration activity was measured using 24-well cell culture
inserts with 8-mm pores (3097, Falcon Becton Dickinson). The
filters were coated with 10 mg of fibronectin (Iwaki Glass) for 12 h
at 4uC. Each lower compartment contained 0.5 mL of serum-free
medium with or without 100 ng/mL recombinant periostin. After
trypsinisation, 56104 cells were resuspended in 100 mL of serum-
free medium and placed in the upper compartment of the cell
culture insert for 4 h. To examine the migration activity, the cells
that had penetrated onto the lower side of the filter were fixed with
formalin and stained with hematoxylin. We counted total number
of the penetrated cells in each assay. The assay was repeated 3
times.
Immunofluorescence analysis
TR-LE cells were seeded on cover slips coated with phosphate-
buffered saline (PBS) or recombinant periostin (200 ng/mL) and
allowed to attach for 60, 120, 180, or 240 min. The cover slips
were washed with PBS and fixed with 4% paraformaldehyde at
room temperature for 10 min, rinsed 3 times with PBS, and then
permeabilized in 0.1% Triton X-100 in PBS for 15 min at room
temperature. After 3 washes with PBS, the cover slips were
incubated in PBS with Alexa Fluor 488-phalloidin (Molecular
Probes, Eugene, OR) and anti-vinculin-FITC (Sigma). DNA was
visualised by 49,6-diamidino-2-phenylindole (DAPI) staining. The
cell preparations were imaged using an epifluorescence Zeiss
Axioplan 2 microscope (Zeiss, Inc.) attached to a CCD camera.
Number of lymphatic vessels in Xenograft model
The anchorage-independent growth of periostin-overexpressing
HNSCC cells in vivo was examined previously [9]. Periostin-
overexpressing HSC2 cells (16107 in 500 mL of Hanks’ balanced
salt solution) were injected subcutaneously (s.c.) at multiple sites in
athymic (nude) mice. The control mice were injected with the
same number of vector-transfected HSC2 cells. The experimental
protocol was approved by the Committee of Research Facilities for
Laboratory Animal Science of Hiroshima University. The animals
were monitored for tumor formation every week and sacrificed
after 1 month. The tumor tissues (10 control and 10 pereiostin-
overexpressing tumors) were fixed in 10% formalin, embedded in
paraffin, and cut into 4-mm-thick sections. The sections were
stained with anti-mouse LYVE-1 antibody (RELIA Tech GmbH,
Wolfenbu¨ttel, Germany) and the numbers of lymphatic vessels
counted. For the evaluation of lymphangiogenesis, we counted and
calculated the average number of lymphatic vessels of over 3 high-
power fields (6100) in each tumor.
Statistical analysis
Possible associations between parameters of the analyzed tumor
samples were tested using the t-test. For the correlation between
vessel infiltration and lymph node status and for the histopatho-
logical grading patterns, statistical significance was measured by
the Chi-square test (x2). For the correlation between periostin
expression and lymph vessel density, statistical significance was
measured by the Welch test. For the correlation between periostin
expression and VEGF-C, statistical significance was measured by
the Chi-square test (x2). For all tests, a P-value ,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Immunohistochemical staining of periostin.
A: Figure shows periostin expression in periodontal ligament. B:
Figures show negative expression of periostin in normal oral
mucosa associated to periostin positive HNSCC cases. Dotted line
separates normal area (normal oral mucosa) without periostin
expression and cancer area (moderately or poorly differentiated
squamous cell carcinoma) with high expression of periostin.
(TIFF)
Figure S2 VEGFR-3 kinase inhibitor suppresses tube
formation by conditioned medium from periostin-
overexpressing cells. A: TR-LE cells were seeded onto
matrigel-coated wells in the presence of conditioned medium
from empty vector-transfected (Control CM), periostin-overex-
pressing (periostin CM) HSC4 cells or recombinant VEGF-C
(100 ng/mL) with or without the VEGFR-3 kinase inhibitor,
MAZ51 (1 mM). After incubation for 0–9 h, the lengths of the
tube-like structures formed were evaluated. Figure shows the cells
after incubation for 9 h. B: The graph shows the tube scores after
incubation for 0–9 h. The bars show the average values and
standard deviations (SDs) from 3 independent experiments. C:
The graph shows the inhibitory ratio of tube formation by MAZ51
after 9 h (%) (right lower panel). The inhibitory ratio of tube
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formation was calculated as ‘100 - (tube score after treatment with
MAZ51/tube score before treatment with MAZ51)6100’.
(TIFF)
Figure S3 Immunohistochemical staining of periostin
in HNSCC cases. A: A representative HNSCC cases of low
expression of Periostin and VEGF-C. B: Figure shows heterog-
enous staining of periostin in HNSCC case with high expression of
periostin. Dotted line shows a representative area of low
expression of periostin.
(TIFF)
Figure S4 Direct involvement of periostin in tube formation of
lymphatic endothelial cells. TR-LE cells were seeded onto
matrigel-coated wells in the presence of periostin (0, 50, 100 or
200 ng/mL). The graph shows the tube score ratios after
treatment with periostin for 9 h. The tube score of control was
defined as 1.0.
(TIFF)
Figure S5 Number of lymphatic vessels in xenograft
periostin-overexpressing tumors. Schema shows the meth-
od to count the number of lymphatic vessels in control and
periostin-overexpressing tumors in xenograft model.
(TIFF)
Figure S6 Periostin did not affect to Flt-4 expression. A:
Expression of Flt-4 and VEGF-C mRNA was examined by RT-
PCR in TR-LE cells after 24 and 48 hr of Periostin treatment
(100 ng/mL). GAPDH expression was used as a loading control.
Two pairs of primer sequences were; rat Flt-4, 59-taaccgacctcctggt-
gaac-39 (forward) and 59-tgcacacactgcacaggtaa-39 (reverse) (prod-
uct size, 204 bp); rat VEGF-C, 59-agcagccacaaacaccttct-39
(forward) and 59-ttagctgcctgacactgtgg-39 (reverse) (product size,
285 bp); rat GAPDH, 59-accacagtccatgccatcac-39 (forward) and
59-tccaccaccctgttgctgta-39 (reverse) (product size, 452 bp). B:
Expression of Flt-4 and VEGF-C mRNA was examined by RT-
PCR in TR-LE cells after 24 hr of Periostin treatment (100, 200
and 400 ng/mL), VEGF-C treatment (500 ng/mL) and Periostin
(100 ng/mL) and VEGF-C (500 ng/mL) treatment.
(TIFF)
Table S1 Clinical data of HNSCC patients and immu-
nohistochemical results.
(TIFF)
Table S2 Clinical data of HNSCC patients and ELISA
result.
(TIFF)
Acknowledgments
We thank Dr. Ajiravudh Subarnhesaj (Hiroshima University) for critical
reading of this manuscript.
Author Contributions
Conceived and designed the experiments: YK. Performed the experiments:
YK SI MY PTN SBSMS T. Tsunematsu MO TA. Analyzed the data: YK
SI MY PTN NI IO T. Takata. Contributed reagents/materials/analysis
tools: YK PTN SBSMS DH TS KKMM. Wrote the paper: YK. Obtained
permission for use of cell line: KK.
References
1. Wen PY, Black PM, Loeffler JS (2001) Treatment of metastatic cancer: Cancer.
In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Principles and Practice of
Oncology. Philadelphia: Lippincott Williams & Wilkins. pp.2655–2670.
2. Fidler IJ (1997) Molecular biology of cancer: invasion and metastasis. In: DeVita
VT Jr, Hellman S, Rosenberg SA, editors. Principles & Practice of Oncology.
Philadelphia: Lippincott Williams & Wilkins. pp.135–152.
3. Stetler-Stevenson WG, Kleiner DE Jr (2001) Molecular biology of cancer:
Invasion and metastases. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors.
Principles and Practice of Oncology. Philadelphia: Lippincott Williams &
Wilkins. pp.123–136.
4. Mao L, Hong WK, Papadimitrakopoulou VA (2004) Focus on head and neck
cancer. Cancer Cell 5: 311–316.
5. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer.
N Engl J Med 345: 1890–1900.
6. Regezi JA, Sciubba JJ (1989) Ulcerative conditions: Clinical-pathologic
correlations. In: Regezi JA, Sciubba JJ, editors. Oral Pathology. Philadelphia:
W. B. Saunders. pp.70–83.
7. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, et al. (2003) Establishment
of an oral squamous cell carcinoma cell line with high invasive and p27
degradation activity from lymph node metastasis. Oral Oncol 39: 515–520.
8. Kudo Y, Kitajima S, Ogawa I, Hiraoka M, Sargolzaei S, et al. (2004) Invasion
and metastasis of oral cancer cells require methylation of E-cadherin and/or
degradation of membranous b-catenin. Clin Cancer Res 10: 5455–5463.
9. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, et al. (2006) Periostin
promotes invasion and anchorage-independent growth in the metastatic process
of head and neck cancer. Cancer Res 66: 6928–6935.
10. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, et al. (1999)
Identification and characterization of a novel protein, Periostin, with restricted
expression to periosteum and periodontal ligament and increased expression by
transforming growth factor beta. J Bone Miner Res 14: 1239–1249.
11. Takeshita S, Kikuno R, Tezuka K, Amann E (1993) Osteoblast-specific factor 2:
cloning of a putative bone adhesion protein with homology with the insect
protein fasciclin I. Biochem J 294: 271–278.
12. Bao S, Ouyang G, Bai X, Huang Z, Ma C, et al. (2004) Periostin potently
promotes metastatic growth of colon cancer by augmenting cell survival via the
Akt/PKB pathway. Cancer Cell 5: 329–339.
13. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, et al. (2004) Acquired
expression of periostin by human breast cancers promotes tumor angiogenesis
through up-regulation of vascular endothelial growth factor receptor 2
expression. Mol Cell Biol 24: 3992–4003.
14. Siriwardena BSMS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, et al. (2006)
Periostin is frequently overexpressed and enhances invasion and angiogenesis in
oral cancer. Br J Cancer 95: 1396–1403.
15. Kudo Y, Siriwardena BS, Ogawa I, Kitagawa M, Kitajima S, et al. (2007)
Periostin: Novel diagnostic and therapeutic target for cancer. Histol Histopathol
22: 1167–1174.
16. Matsuo M, Koizumi K, Yamada S, Tomi M, Takahashi R, et al. (2006)
Establishment and characterization of conditionally immortalized endothelial
cell lines from the thoracic duct and inferior vena cava of tsA58/EGFP double-
transgenic rats. Cell Tissue Res 326: 749–758.
17. Kirkin V, Mazitschek R, Krishnan J, Steffen A, Waltenberger J, et al. (2001)
Characterization of indolinones which preferentially inhibit VEGF- and VEGF-
D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem 268:
5530–5540.
18. Hamada K, Oike Y, Takakura N, Ito Y, Jussila L, et al. (2000) VEGF-C
signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis
and hematopoiesis. Blood 96: 3793–3800.
19. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, et al. (1998) Vascular
endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci
USA 95: 14389–14394.
20. Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, et al. (2006)
VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic
brain. Nat Neurosci 9: 340–348.
21. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K (2004) Lymphatic
vasculature: Development, molecular regulation and role in tumor metastasis
and inflammation. Trends Immunol 25: 387–395.
22. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, et al. (2002) Intratumoral
lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer
Res 62: 1315–1320.
23. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, et al. (2003) The
tumor lymphangiogenesis: A novel prognostic indicator for cutaneous melanoma
metastasis and survival. Am J Pathol 162: 1951–1960.
24. Siriwardena BS, Kudo Y, Ogawa I, Udagama MN, Tilakaratne WM, et al.
(2008) VEGF-C is associated with lymphatic status and invasion in oral cancer.
J Clin Pathol 61: 103–108.
25. Litvin J, Selim AH, Montgomery MO, Lehmann K, Rico MC, et al. (2004)
Expression and function of periostin-isoforms in bone. J Cell Biochem 92: 1044–
1061.
26. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, et al. (1994)
Integrin alpha v beta 3 antagonists promote tumor regression by inducing
apoptosis of angiogenic blood vessels. Cell 79, 1157–1164.
27. Scatena M, Giachelli C (2002) The alpha(v)beta3 integrin, NFkappaB,
osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis.
Trends Cardiovasc Med 12: 83–88.
28. Stupack DG, Cheresh DA (2002) Get a ligand, get a life: Integrins, signaling and
cell survival. J Cell Sci 115: 3729–3738.
Periostin Promotes Tumor Lymphangiogenesis
PLOS ONE | www.plosone.org 13 August 2012 | Volume 7 | Issue 8 | e44488
29. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, et al. (1996) A novel
vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3)
and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290–298.
30. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, et al. (1996) Vascular endothelial
growth factor-related protein: A ligand and specific activator of the tyrosine
kinase receptor Flt4. Proc Natl Acad Sci USA 93: 1988–1992.
31. Eriksson U, Alitalo K (1999) Structure, expression and receptor-binding
properties of novel vascular endothelial growth factors. Curr Top Microbiol
Immunol 237: 41–57.
32. Ferrara N (1999) Vascular endothelial growth factor: Molecular and biological
aspects. Curr Top Microbiol Immunol 237: 1–30.
33. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, et al. (1996) VEGF-C
receptor binding and pattern of expression with VEGFR-3 suggests a role in
lymphatic vascular development. Development 122: 3829–3837.
34. Lymboussaki A, Olofsson B, Eriksson U, Alitalo K (1999) Vascular endothelial
growth factor (VEGF) and VEGF-C show overlapping binding sites in
embryonic endothelia and distinct sites in differentiated adult endothelia. Circ
Res 85: 992–999.
35. Lymboussaki A, Olofsson B, Eriksson U, Alitalo K (1997) Hyperplasia of
lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423–1425.
36. Oh SJ, Jeltsch MM, Birkenha¨ger R, McCarthy JE, Weich HA, et al. (1997)
VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis
in the differentiated avian chorioallantoic membrane. Dev Biol 188: 96–109.
37. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, et al. (2007) The role of the
VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96: 541–545.
38. Hong L, Sun H, Lv X, Yang D, Zhang J, Shi Y (2010) Expression of periostin in
the serum of NSCLC and its function on proliferation and migration of human
lung adenocarcinoma cell line (A549) in vitro. Mol Biol Rep 37: 2285–2293.
39. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ (2009) Circulating levels of
periostin may help identify patients with more aggressive colorectal cancer.
Int J Oncol 34: 821–828.
40. Sasaki H, Yu CY, Dai M, Tam C, Loda M, et al. (2003) Elevated serum
periostin levels in patients with bone metastases from breast but not lung cancer.
Breast Cancer Res Treat 77: 245–252.
41. Fujimoto K, Kawaguchi T, Nakashima O, Ono J, Ohta S, et al. (2011) Periostin,
a matrix protein, has potential as a novel serodiagnostic marker for
cholangiocarcinoma. Oncol Rep 25: 1211–1216.
42. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV (2007)
Mechanisms of integrin-vascular endothelial growth factor receptor cross-
activation in angiogenesis. Circ Res 101: 570–580.
43. Mahabeleshwar GH, Chen J, Feng W, Somanath PR, Razorenova OV, et al.
(2008) Integrin affinity modulation in angiogenesis. Cell Cycle 7: 335–347.
44. Galvagni F, Pennacchini S, Salameh A, Rocchigiani M, Neri F, et al. (2010)
Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent
VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase
activity. Circ Res 106: 1839–1848.
45. Zhou F, Chang Z, Zhang L, Hong YK, Shen B, et al. (2010) Akt/Protein kinase
B is required for lymphatic network formation, remodeling, and valve
development. Am J Pathol 177: 2124–2133.
46. Ma¨kinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, et al. (2001)
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice
expressing soluble VEGF receptor-3. Nat Med 7: 199–205.
47. Ischenko I, Seeliger H, Camaj P, Kleespies A, Guba M, et al. (2010) Src tyrosine
kinase inhibition suppresses lymphangiogenesis in vitro and in vivo. Curr Cancer
Drug Targets 10: 546–553.
48. Ristima¨ki A, Narko K, Enholm B, Joukov V, Alitalo K (1998) Proinflammatory
cytokines regulate expression of the lymphatic endothelial mitogen Vascular
Endothelial Growth Factor-C. J Biol Chem 273: 8413–8418.
49. Takanami I, Abiko T, Koizumi S (2008) Expression of periostin in patients with
non-small cell lung cancer: Correlation with angiogenesis and lymphangiogen-
esis. Int J Biol Markers 23: 182–186.
50. Ben QW, Jin XL, Liu J, Cai X, Yuan F, et al. (2011) Periostin, a matrix specific
protein, is associated with proliferation and invasion of pancreatic cancer. Oncol
Rep 25: 709–716.
51. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, et al. (2010)
Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals
alterations related to tumor progression and indicates periostin as a poor
prognostic marker. Mol Cancer 9: 13.
52. Bai Y, Kakudo K, Nakamura M, Ozaki T, Li Y, et al. (2009) Loss of cellular
polarity/cohesiveness in the invasive front of papillary thyroid carcinoma and
periostin expression. Cancer Lett 281: 188–195.
53. Tilman G, Mattiussi M, Brasseur F, van Baren N, Decottignies A (2007) Human
periostin gene expression in normal tissues, tumors and melanoma: evidences for
periostin production by both stromal and melanoma cells. Mol Cancer 6: 80.
54. Li JS, Sun GW, Wei XY, Tang WH (2007) Expression of periostin and its
clinicopathological relevance in gastric cancer. World J Gastroenterol 13: 5261–
5266.
Periostin Promotes Tumor Lymphangiogenesis
PLOS ONE | www.plosone.org 14 August 2012 | Volume 7 | Issue 8 | e44488
